Beckman Coulter Now an Authorized Distributor
of MeMed Key Immunoassay System and MeMed BV Assay
Progress Continues on Original Collaboration
to Develop a MeMed BV-Based Assay for use on Beckman Coulter
Immunoassay Analyzers
BREA,
Calif. and HAIFA,
Israel, May 7, 2024 /PRNewswire/ -- Beckman
Coulter Diagnostics, a global leader in clinical diagnostics, and
MeMed, a leader in the emerging field of advanced host-response
technologies, today announced expansion of their host immune
response diagnostics partnership. Beckman Coulter is now an
authorized distributor of the MeMed BV® assay, a rapid
immunoassay test able to distinguish between bacterial and viral
infections, and MeMed Key®, a compact immunoassay analyzer
cleared to run the MeMed BV assay in the
United States and Europe.
This new distribution agreement complements the existing joint
effort to develop a MeMed BV-based test for Beckman Coulter's
family of Access Immunoassay Analyzers.
Symptoms of bacterial and viral infections are often clinically
indistinguishable, which creates challenges for physicians when
deciding to start treating patients with antibiotics or not.
Unfortunately, this ambiguity can result in the underuse and
overuse of antibiotics. Recent research published in
Biomedicines showed that up to 29% of the time, clinicians
face uncertainty in differentiating bacterial versus viral
infections, which can cause delays in clinical decision-making and
inefficient diagnostic workflows. This research report indicated
that the MeMed BV assay supported or altered physician
decision-making in 87% of cases (p < 0.05). MeMed BV returns
results in 15 minutes from serum or whole blood and has >99%
negative predictive value (NPV)* to rule out bacterial infection.
1-3
"Beckman Coulter's commitment to improving infection management
is unwavering," said Kevin O'Reilly,
President, Beckman Coulter. "To that end, we are excited to extend
our partnership with MeMed by expanding market access to the MeMed
Key and BV assay. These MeMed innovations complement Beckman
Coulter's portfolio of host response diagnostics, including our
CBC-based hematological biomarker MDW [monocyte distribution width]
identifying the presence of severe infection and risk of sepsis,
our clinical chemistry PCT [procalcitonin] assay aiding risk
assessment for septic shock, and our full suite of microbiology
solutions providing faster time to optimize antibiotic
therapies."
Dr. Eran Eden, MeMed's CEO and
co-founder, added: "We're excited to expand our partnership with
Beckman Coulter, taking an additional step forward in our shared
mission to advance pioneering host-response solutions. This
expansion focuses on two main objectives: first, to educate and
prime the market to accelerate the adoption of MeMed BV once it's
cleared for use on Beckman Coulter's core-lab immunoassay
analyzers; second, to broaden patient access to MeMed BV through a
strategic hub and spoke model. By combining the capabilities of
Beckman Coulter's analyzers with the MeMed Key's ability to deliver
results directly from whole blood within minutes, we're creating a
synergistic ecosystem that aids clinicians in distinguishing
between bacterial and viral infections with unprecedented ease and
precision."
MeMed BV is a diagnostic test developed to address management of
patients with acute infection in different clinical settings,
including Emergency Departments. The MeMed BV test uses a machine
learning-derived algorithm to integrate measurements of three key
host-immune proteins (TRAIL, IP-10, and CRP) into a score
indicating the likelihood of bacterial or viral infections. The
performance has been validated on the MeMed Key by world class
institutions in multi-national blinded validation studies as well
as rapidly growing real-world use in the U.S. and EU, altogether in
over 20,000 patients.1-5 MeMed BV on MeMed Key is US FDA
cleared, CE-Marked and approved by the Israeli Ministry of
Health.
About MeMed
At MeMed, our mission is to translate the immune system's
complex signals into simple insights that transform the way
diseases are diagnosed and treated, profoundly benefiting patients
and society.
Follow and connect with MeMed via LinkedIn, X, and Facebook.
About Beckman Coulter. Inc.
A global leader in advanced diagnostics, Beckman Coulter has
challenged convention to elevate the diagnostic laboratory's role
in improving patient health for more than 80 years. Our mission is
to Relentlessly Reimagine Healthcare, One Diagnosis at a Time – and
we do this by applying the power of science, technology and the
passion and creativity of our teams. Our diagnostic solutions are
used in complex clinical testing, and are found in hospitals,
reference laboratories and physician office settings around the
globe. We exist to deliver smarter, faster diagnostic solutions
that move the needle forward from what's now to what's next. We
seek to accelerate care with an extensive clinical menu, scalable
lab automation technologies, insightful clinical informatics, and
optimize lab performance services. Headquartered in Brea, Calif., with more than 11,000 global
team members, Beckman Coulter Diagnostics is proud to be part of
Danaher. Danaher is a global science and technology leader.
Together we combine our capabilities to accelerate the real-life
impact of tomorrow's science and technology to improve human
health.
Follow and connect with Beckman Coulter Diagnostics via
LinkedIn, X, and Facebook.
1 Halabi et al. Clinical Microbiology and
Infection, 2023;
2 Papan et al. Clinical Microbiology and Infection,
2022;
3 Data on file. Based on secondary endpoint
analysis in Apollo Clinical Study (NCT04690569) conducted to
establish the diagnostic performance of the MeMed BV Test for
differentiating bacterial from viral infection in patients with
suspected cute bacterial or viral infection;
4 Klein et al. Pediatrics, 2023,
5 van Houten et al. Lancet ID, 2016.
© 2024 Beckman Coulter. All rights reserved. Beckman Coulter,
the stylized logo, and the Beckman Coulter product and service
marks mentioned herein are trademarks or registered trademarks of
Beckman Coulter, Inc. in the United
States and other countries. MeMed, MeMed Key, and MeMed
BV are trademarks or registered trademarks of MeMed Diagnostics
Ltd. in the United States and
other countries. 2024-12879.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/beckman-coulter-and-memed-extend-partnership-advancing-host-immune-response-diagnostics-302137475.html
SOURCE Beckman Coulter Diagnostics